Zimbabwe has taken a decisive step in strengthening its public health response by rolling out Lenacapavir, a long-acting HIV prevention injection administered just twice a year, positioning the country among the first global adopters of next-generation HIV prevention technologies.
The move reflects a deliberate shift towards innovative, sustainable and evidence-driven healthcare solutions as Zimbabwe accelerates progress towards ending AIDS as a public health threat by 2030.
The phased rollout has been carefully structured to maximise public health impact. The Government has prioritised 12 high-incidence districts and major urban centres, including Harare, Bulawayo, Gweru, Masvingo and Mutare, areas with both elevated HIV risk and strong existing prevention infrastructure.
Rainbow Hotels — Experience Luxury Across Zimbabwe
Rainbow Hotels continues to redefine hospitality standards in Zimbabwe, offering world-class accommodation, fine dining, and modern conference facilities in Harare, Bulawayo, and Victoria Falls.
Whether for business or leisure, Rainbow Hotels delivers unmatched comfort, exceptional service, and a truly premium guest experience tailored to modern travellers.
Book NowThis targeted approach underscores a commitment to data-led planning and efficient deployment of limited health resources, ensuring that innovation translates into measurable outcomes rather than symbolic policy gestures.
Approximately 46,500 people are expected to benefit in the initial phase, with a deliberate focus on adolescent girls and young women, sex workers, and other vulnerable populations who continue to bear a disproportionate burden of new HIV infections. By prioritising these groups, the programme reinforces a people-centred health strategy that places equity, protection and inclusion at the core of national health policy.
Beyond its clinical advantages, Lenacapavir addresses long-standing adherence challenges associated with daily oral prevention pills. The twice-yearly injection offers a practical and discreet alternative, particularly for individuals facing social, economic or structural barriers to consistent medication use.
In this regard, the rollout represents not only a biomedical advancement but also a behavioural and social breakthrough in HIV prevention.
The initiative has been made possible through strong global partnerships, notably with Gilead Sciences and the Global Fund, which is financing the medication. These collaborations highlight Zimbabwe’s growing credibility as a reliable partner in global health and its ability to mobilise international support in alignment with national priorities.
Taken together, the Lenacapavir rollout signals a maturing public health system that is increasingly anchored in innovation, strategic targeting and long-term sustainability.
As implementation progresses, Zimbabwe’s experience is likely to offer valuable lessons for the region, reinforcing its role as a leader in progressive, forward-looking HIV prevention strategies.
